Publication:
Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae - Authors' reply.

dc.contributor.authorGutierrez-Gutierrez, Belen
dc.contributor.authorBonomo, Robert A
dc.contributor.authorCarmeli, Yehuda
dc.contributor.authorPaterson, David L
dc.contributor.authorPascual, Alvaro
dc.contributor.authorRodriguez-Baño, Jesus
dc.date.accessioned2023-01-25T10:00:36Z
dc.date.available2023-01-25T10:00:36Z
dc.date.issued2017
dc.description.abstractWe thank Bernd Salzberger and Gerd Fätkenheuer for their interest in our study.1 They were concerned about the use of Charlson, Pitt, and INCREMENT-CPE scores, as well as the individual variables contained in them in the analyses. Our objective was to provide the best possible estimation of the association of the main exposure ( treatment ) with the outcome considering the effect of confounders, in accordance with the study hypothesis; we did not intend to provide a model to predict outcome ( mortality ). Therefore, we did several multivariate analyses , including models with the individual variables, models with the scores, and models with both, after checking for collinearity. The best models were selected and are shown in tables 2 and 3 of our paper .1 As a result, when the scores were considered, the individual variables were not relevant and the effect of treatment on mortality was adjusted by the scores.
dc.description.versionNo
dc.identifier.citationGutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J. Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae - Authors' reply. Lancet Infect Dis. 2017 Oct;17(10):1020-1021.
dc.identifier.doi10.1016/S1473-3099(17)30522-4
dc.identifier.essn1474-4457
dc.identifier.pmid28948921
dc.identifier.unpaywallURLhttp://www.thelancet.com/article/S1473309917305224/pdf
dc.identifier.urihttp://hdl.handle.net/10668/11609
dc.issue.number10
dc.journal.titleThe Lancet. Infectious diseases
dc.journal.titleabbreviationLancet Infect Dis
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen Macarena
dc.page.number1020-1021
dc.provenanceRealizada la curación de contenido 03/04/2025
dc.publisherThe Lancet Publishing Group
dc.pubmedtypeLetter
dc.pubmedtypeComment
dc.relation.publisherversionhttps://linkinghub.elsevier.com/retrieve/pii/S1473-3099(17)30522-4
dc.rights.accessRightsRestricted Access
dc.subjectAnti-Bacterial Agents
dc.subjectBacterial Proteins
dc.subjectEnterobacteriaceae
dc.subjectHumans
dc.subjectbeta-Lactamases
dc.subject.decsMortalidad
dc.subject.decsTerapéutica
dc.subject.decsAnálisis multivariante
dc.subject.decsPapel
dc.subject.decsReflujo gastroesofágico
dc.subject.decsAsociación
dc.subject.meshBacteremia
dc.subject.meshCarbapenem-Resistant Enterobacteriaceae
dc.subject.meshEnterobacteriaceae Infections
dc.subject.meshMicrobial Sensitivity Tests
dc.titleCombination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae - Authors' reply.
dc.typeletter
dc.type.hasVersionVoR
dc.volume.number17
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format